Question explored with the scientific record
Conversation so far
- 1 Is ACI-24.060 a promising drug for Alzheimer’s
- 2 What phase is ACI-24.060 in, and when are results expected?
- 3 Is ACI-24.060 registered on ClinicalTrials.gov or EU CTR?
- 4 Are there any IRB/press-release/manufacturer updates on ACI-24.060?
Answered on this page ↓
Are there any IRB/press-release/manufacturer updates on ACI-24.060?
The short version: nothing retrieved shows an IRB approval, a press release, or a manufacturer update for ACI-24.060.
The records in front of me don't touch ACI-24.060 at all. What came back is a stray set: cartilage repair, tilapia genetics, rat breast cancer, concrete beams [1][2][3][4]. None of it is a company announcement, a regulatory filing, or an ethics-committee decision about this vaccine.
That absence is a fact about the search, not about the world. A press release, an IRB approval letter, or a sponsor update lives on company and registry pages, not in the journal literature these searches pull from. So I can't confirm any of the three exist, and I can't confirm they don't. IRB approvals in particular are usually private unless a trial is registered or the sponsor chooses to publicize them.
The honest underwriting answer: an experimental Alzheimer's vaccine in early human testing should have a registered trial, a named sponsor, and a stated phase before "updates" mean anything. None of that is visible here. The most useful check is the sponsor's own newsroom and the trial registries, searched directly, the same step I flagged last turn.
My call: no IRB, press-release, or manufacturer update for ACI-24.060 is confirmed by anything retrieved. Confidence: high that these records contain none; not clear on whether any exist.
Sources used 4
-
Advances in the Surgical Management of Articular Cartilage Defects
Newer cell-based cartilage repair products show promising but inconsistent clinical results, but no product is clearly superior to microfracture and randomized head-to-head comparisons among the newer techniques are lacking.
DOI: 10.1177/1947603512463226 -
Multi-trait GWAS using imputed high-density genotypes from whole-genome sequencing identifies genes associated with body traits in Nile tilapia
Imputing whole-genome sequence data and applying multi-trait GWAS to Nile tilapia identifies QTL and candidate genes for eight body traits, with mtGWAS increasing discovery power (~44% equivalent sample size) and revealing major signals on LG12 (shared across traits) and LG13 fo…
DOI: 10.1186/s12864-020-07341-z -
Effect of a tissue selective estrogen complex on breast cancer: Role of unique properties of conjugated equine estrogen
In rat models, CEE did not stimulate breast tumor development like estradiol, induced apoptosis rather than proliferation, and bazedoxifene blocked estrogen-driven tumors, suggesting CEE/BZA may reduce breast cancer risk.
DOI: 10.1002/ijc.31401 -
Efficiency of near surface mounted technique using fiber reinforced polymers for the flexural strengthening of RC beams
In ten full-scale RC beams, NSM FRP strengthening increased ultimate flexural capacity by 31–133%; CFRP gave higher capacity, GFRP better ductility, and hybrid NSM+EB offered no clear advantage.
DOI: 10.1016/j.conbuildmat.2016.04.152